Safety of bevacizumab in mild haemophilia B

Thromb Haemost. 2008 May;99(5):963-4. doi: 10.1160/TH07-12-0717.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / adverse effects
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bevacizumab
  • Chemotherapy, Adjuvant
  • Colonic Neoplasms / blood
  • Colonic Neoplasms / complications
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / pathology
  • Hemophilia B / blood
  • Hemophilia B / complications*
  • Hemophilia B / drug therapy
  • Hemorrhage / blood
  • Hemorrhage / chemically induced
  • Hemostasis / drug effects
  • Humans
  • Liver Neoplasms / blood
  • Liver Neoplasms / complications
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / secondary
  • Male
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab